Gynecology_Novak

Gynecology_Novak. 291. Vuorela P, Carp´en O, Tulppala M, et al. VEGF, its receptors and the tie receptors in recurrent miscarriage. Mol Hum Reprod 2000;6:276– 282. 292. Lessey BA. Endometrial integrins and the establishment of uterine receptivity. Hum Reprod 1998;13(Suppl 3):247–261. 293. Aplin JD, Hey NA, Li TC. MUC1 as a cell surface and secretory component of endometrial epithelium: reduced levels in recurrent miscarriage. Am J Reprod Immunol 1996;35:261–266. 294. Gaffuri B, Airoldi L, Di Blasio AM, et al. Unexplained habitual abortion is associated with a reduced endometrial release of soluble intercellular adhesion molecule-1 in the luteal phase of the cycle. Eur J Endocrinol 2000;142:477–480. 295. Lea RG, al-Sharekh N, Tulppala M, et al. The immunolocalization of bcl-2 at the maternal-fetal interface in healthy and failing pregnancies. Hum Reprod 1997;12:153–158. 296.


Gynecology_Novak

Gynecology_Novak. 295. Lea RG, al-Sharekh N, Tulppala M, et al. The immunolocalization of bcl-2 at the maternal-fetal interface in healthy and failing pregnancies. Hum Reprod 1997;12:153–158. 296. Polifka JE, Friedmann JM. Environmental toxins and recurrent pregnancy loss. Infert Reprod Med Clin North Am 1991;2:195–213. 297. Sharara FI, Seifer DB, Flaws JA. Environmental toxicants and female reproduction. Fertil Steril 1998;70:613–622. 298. Valanis B, Vollmer WM, Steele P. Occupational exposure to anti-neoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med 1999;41:632–638. 299. Xu X, Cho SI, Sammel M, et al. Association of petrochemical exposure with spontaneous abortion. Occup Environ Med 1998;55: 31–36. 300. Sugiura-Ogasawara M, Ozaki Y, Sonta S, et al. Exposure to bisphenol A is associated with recurrent miscarriage. Hum Reprod 2005;20:2325–2329. 301.


Gynecology_Novak

Gynecology_Novak. 300. Sugiura-Ogasawara M, Ozaki Y, Sonta S, et al. Exposure to bisphenol A is associated with recurrent miscarriage. Hum Reprod 2005;20:2325–2329. 301. Gerhard I, Waibel S, Daniel V, et al. Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages. Hum Reprod Update 1998;4:301–309. 302. Cone JE, Vaughan LM, Huete A, et al. Reproductive health outcomes among female ﬂight attendants: an exploratory study. J Occup Environ Med 1998;40:210–216. 303. Schnorr TM, Grajewski BA, Hornung RW, et al. Video display terminals and the risk of spontaneous abortion. N Engl J Med 1991;324:727–733. 304. Kurki T, Ylikorkala O. Coitus during pregnancy is not related to bacterial vaginosis or preterm birth. Am J Obstet Gynecol 1993;169:1130–1134. 305. Naeye RL. Coitus and associated amniotic-ﬂuid infections. N Engl J Med 1979;301:1198–1200. 306. Abel EL. Maternal alcohol consumption and spontaneous abortion. Alcohol Alcohol 1997;32:211–219. 307.


Gynecology_Novak

Gynecology_Novak. 306. Abel EL. Maternal alcohol consumption and spontaneous abortion. Alcohol Alcohol 1997;32:211–219. 307. Parazzini F, Tozzi L, Chatenoud L, et al. Alcohol and risk of spontaneous abortion. Hum Reprod 1994;9:1950–1953. 308. Windham GC, Siscovick DS, Raghunathan TE, et al. Moderate maternal alcohol consumption and risk of spontaneous abortion. Epidemiology 1997;8:509–514. 309. Cnattingius S, Signorello LB, Anner´en G, et al. Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med 2000;343:1839–1845. 310. Ness RB, Grisso JA, Hirschinger N, et al. Cocaine and tobacco use and the risk of spontaneous abortion. N Engl J Med 1999;340:333– 339. 311. Kline J, Levin B, Kinney A, et al. Cigarette smoking and spontaneous abortion of known karyotype. Precise data but uncertain inferences. Am J Epidemiol 1995;141:417–427. 312.


Gynecology_Novak

Gynecology_Novak. 311. Kline J, Levin B, Kinney A, et al. Cigarette smoking and spontaneous abortion of known karyotype. Precise data but uncertain inferences. Am J Epidemiol 1995;141:417–427. 312. Hedin LW, Janson PO. Domestic violence during pregnancy. The prevalence of physical injuries, substance use, abortions and miscarriages. Acta Obstet Gynecol Scand 2000;79:625–630. 313. Mills JL, Holmes LB, Aarons JH, et al. Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth retardation. JAMA 1993;269:593–597. 314. Bellver J, Rossal LP, Bosch E, et al. Obesity and the risk of spontaneous abortion after oocyte donation. Fertil Steril 2003;79:1136– 1140. 315. Brandt LP, Nielsen CV. Job stress and adverse outcome of pregnancy: a causal link or recall bias? Am J Epidemiol 1992;135:302– 311. 316. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inﬂammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003;327:368. 317.


Gynecology_Novak

Gynecology_Novak. 316. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inﬂammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003;327:368. 317. Nielsen GL, Sørensen HT, Larsen H, et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inﬂammatory drugs: population based observational study and case-control study. BMJ 2001;322:266–270. 318. Boue J, Bou A, Lazar P. Retrospective and prospective epidemiological studies of 1500 karyotyped spontaneous human abortions. Teratology 1975;12:11–26. 319. Stein Z. Early fetal loss. Birth Defects Orig Artic Ser 1981;17:95– 111. 320. Hook EB, Warburton D. The distribution of chromosomal genotypes associated with Turner’s syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. Hum Genet 1983;64:24–27. 321.


Gynecology_Novak

Gynecology_Novak. 321. Heuser C, Dalton J, Macpherson C, et al. Idiopathic recurrent pregnancy loss recurs at similar gestational ages. Am J Obstet Gynecol 2010;203:343.e1–e5. 322. Miller JF, Williamson E, Glue J, et al. Fetal loss after implantation. A prospective study. Lancet 1980;2:554–556. 323. Boue JG, Boue A. Increased frequency of chromosomal anomalies in abortions after induced ovulation. Lancet 1973;1:679–680. 324. Olpin, JD, Heilbrun M. Imaging of Mullerian duct anomalies. Clin Obstet Gynecol 2009;52:40–56. 325. Makhseed M, Raghupathy R, Azizieh F, et al. Circulating cytokines and CD30 in normal human pregnancy and recurrent spontaneous abortions. Hum Reprod 2000;15:2011–2017. 326. Aoki K, Kajiura S, Matsumoto Y, et al. Preconceptional natural-killer-cell activity as a predictor of miscarriage. Lancet 1995;345:1340–1342. 327.


Gynecology_Novak

Gynecology_Novak. 326. Aoki K, Kajiura S, Matsumoto Y, et al. Preconceptional natural-killer-cell activity as a predictor of miscarriage. Lancet 1995;345:1340–1342. 327. Emmer PM, Nelen WL, Steegers EA, et al. Peripheral natural killer cytotoxicity and CD56(pos)CD16(pos) cells increase during early pregnancy in women with a history of recurrent spontaneous abortion. Hum Reprod 2000;15:1163–1169. 328. Branch DW, Silver R, Pierangeli S, et al. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997;89:549– 555. 329. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996;66:540–546. 330.


Gynecology_Novak

Gynecology_Novak. 330. Gris JC, Qu´er´e I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study—NOHA. Thromb Haemost 2000;84:228–236. 331. Mavragani CP, Ioannidis JP, Tzioufas AG, et al. Recurrent pregnancy loss and autoantibody profile in autoimmune diseases. Rheumatology (Oxford) 1999;38:1228–1233. 332. Duggan MA, Brashert P, Ostor A, et al. The accuracy and interobserver reproducibility of endometrial dating. Pathology 2001;33:292–297. 333. Murray MJ, Meyer WR, Zaino RJ, et al. A critical analysis of the accuracy, reproducibility, and clinical utility of histologic endometrial dating in fertile women. Fertil Steril 2004;81:1333–1343. 334. Coulam CB, Wagenknecht D, McIntyre JA, et al. Occurrence of other reproductive failures among women with recurrent spontaneous abortion. Am J Reprod Immunol 1991;25:96–98. 335.


Gynecology_Novak

Gynecology_Novak. 334. Coulam CB, Wagenknecht D, McIntyre JA, et al. Occurrence of other reproductive failures among women with recurrent spontaneous abortion. Am J Reprod Immunol 1991;25:96–98. 335. Fedele L, Acaia B, Parazzini F, et al. Ectopic pregnancy and recurrent spontaneous abortion: two associated reproductive failures. Obstet Gynecol 1989;73:206–208. 336. Acaia B, Parazzini F, La Vecchia C, et al. Increased frequency of complete hydatidiform mole in women with repeated abortion. Gynecol Oncol 1988;31:310–314. 337. Hughes N, Hamilton EF, Tulandi T. Obstetric outcome in women after multiple spontaneous abortions. J Reprod Med 1991;36:165– 166. 338. Martius JA, Steck T, Oehler MK, et al. Risk factors associated with preterm (<37+0 weeks) and early preterm birth (<32+0 weeks): univariate and multivariate analysis of 106,345 singleton births from the 1994 statewide perinatal survey of Bavaria. Eur J Obstet Gynecol Reprod Biol 1998;80:183–189. 339.


Gynecology_Novak

Gynecology_Novak. 339. Lird T, Whittaker PG. The endocrinology of early pregnancy loss. In: Huisjes HJ, Lird T, eds. Early pregnancy failure. New York: Churchill Livingstone, 1990:39–54. 340. Westergaard JG, Teisner B, Sinosich MJ, et al. Does ultrasound examination render biochemical tests obsolete in the prediction of early pregnancy failure? Br J Obstet Gynaecol 1985;92:77–83. 341. Li TC, Spring PG, Bygrave C, et al. The value of biochemical and ultrasound measurements in predicting pregnancy outcome in women with a history of recurrent miscarriage. Hum Reprod 1998;13:3525– 3529. 342. Wolf GC, Horger EO 3rd. Indications for examination of spontaneous abortion specimens: a reassessment. Am J Obstet Gynecol 1995;173:1364–1368. 343. Tachdjian G, Aboura A, Lapierre JM, et al. Cytogenetic analysis from DNA by comparative genomic hybridization. Ann Genet 2000;43:147–154. 344.


Gynecology_Novak

Gynecology_Novak. 343. Tachdjian G, Aboura A, Lapierre JM, et al. Cytogenetic analysis from DNA by comparative genomic hybridization. Ann Genet 2000;43:147–154. 344. Bell KA, Van Deerlin PG, Feinberg RF, et al. Diagnosis of aneuploidy in archival, paraffin-embedded pregnancy-loss tissues by comparative genomic hybridization. Fertil Steril 2001;75:374–379. 345. Bianchi DW, Flint AF, Pizzimenti MF, et al. Isolation of fetal DNA from nucleated erythrocytes in maternal blood. Proc Natl Acad Sci USA 1990;87:3279–3283. 346. Carp H, Toder V, Aviram A, et al. Karyotype of the abortus in recurrent miscarriage. Fertil Steril 2001;75:678–682. 347. Garrisi JG, Colls P, Ferry KM, et al. Effect of infertility, maternal age, and number of previous miscarriages on the outcome of preimplantation genetic diagnosis for idiopathic recurrent pregnancy loss. Fertil Steril 2009;92:288–295. 348.


Gynecology_Novak

Gynecology_Novak. 348. Fischer J, Colls P, Escudero T, et al. Preimplantation genetic diagnosis (PGD) improves pregnancy outcome for translocation carriers with a history of recurrent losses. Fertil Steril 2010;94:283–289. 349. Munn´e S, Chen S, Fischer J, et al. Preimplantation genetic diagnosis reduces pregnancy loss in women aged 35 years and older with a history of recurrent miscarriages. Fertil Steril 2005;84:331–335. 350. Munn´e S, Fischer J, Warner A, et al. Preimplantation genetic diagnosis significantly reduces pregnancy loss in infertile couples: a multicenter study. Fertil Steril 2006;85:326–332. 351. Verlinsky Y, Cohen J, Munne S, et al. Over a decade of experience with preimplantation genetic diagnosis: a multicenter report. Fertil Steril 2004;82:292–294. 352. Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med 2007;357:9–17. 353.


Gynecology_Novak

Gynecology_Novak. 352. Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med 2007;357:9–17. 353. Twisk M, Mastenbroek S, Hoek A, et al. No beneficial effect of preimplantation genetic screening in women of advanced maternal age with a high risk for embryonic aneuploidy. Hum Reprod 2008;23:2813–2817. 354. Staessen C, Verpoest W, Donoso P, et al. Preimplantation genetic screening does not improve delivery rate in women under the age of 36 following single-embryo transfer. Hum Reprod 2008;23:2818– 2825. 355. Staessen C, Platteau P, Van Assche E, et al. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. Hum Reprod 2004;19:2849– 2858. 356.


Gynecology_Novak

Gynecology_Novak. 356. Meyer LR, Klipstein S, Hazlett WD, et al. A prospective randomized controlled trial of preimplantation genetic screening in the “good prognosis” patient. Fertil Steril 2009;91:1731–1738. 357. Hardarson T, Hanson C, Lundin K, et al. Preimplantation genetic screening in women of advanced maternal age caused a decrease in clinical pregnancy rate: a randomized controlled trial. Hum Reprod 2008;23:2806–2812. 358. Remoh´J, Gallardo E, Levy M, et al. Oocyte donation in women with recurrent pregnancy loss. Hum Reprod 1996;11:2048–3051. 359. Querleu D, Brasme TL, Parmentier D. Ultrasound-guided transcervical metroplasty. Fertil Steril 1990;54:995–998. 360. Karande VC, Gleicher N. Resection of uterine septum using gynaecoradiological techniques. Hum Reprod 1999;14:1226–1229. 361. Raziel A, Herman A, Strassburger D, et al. The outcome of in vitro fertilization in unexplained habitual aborters concurrent with secondary infertility. Fertil Steril 1997;67:88–92. 362.


Gynecology_Novak

Gynecology_Novak. 361. Raziel A, Herman A, Strassburger D, et al. The outcome of in vitro fertilization in unexplained habitual aborters concurrent with secondary infertility. Fertil Steril 1997;67:88–92. 362. Fedele L, Bianchi S. Habitual abortion: endocrinological aspects. Curr Opin Obstet Gynecol 1995;7:351–356. 363. Karamardian LM, Grimes DA. Luteal phase deficiency: effect of treatment on pregnancy rates. Am J Obstet Gynecol 1992;167:1391– 1398. 364. Clifford K, Rai R, Watson H, et al. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. BMJ 1996;312:1508–1511. 365. Glueck CJ, Wang P, Goldenberg N, et al. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004;10:323–334. 366. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524–529. 367.


Gynecology_Novak

Gynecology_Novak. 366. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524–529. 367. Hill JA. Immunological mechanisms of pregnancy maintenance and failure: a critique of theories and therapy. Am J Reprod Immunol 1990;22:33–41. 368. Hill JA. Immunotherapy for recurrent pregnancy loss: “standard of care or buyer beware.” J Soc Gynecol Investig 1997;4:267–273. 369. Stovall DW, Van Voorhis BJ. Immunologic tests and treatments in patients with unexplained infertility, IVF-ET, and recurrent pregnancy loss. Clin Obstet Gynecol 1999;42:979–1000. 370. Stephenson M, Kutteh W. Evaluation and management of recurrent early pregnancy loss. Clin Obstet Gynecol 2007;50:132–145. 371. Agrawal S, Pandey MK, Pandey A. Prevalence of MLR blocking antibodies before and after immunotherapy. J Hematother Stem Cell Res 2000;9:257–262. 372.


Gynecology_Novak

Gynecology_Novak. 371. Agrawal S, Pandey MK, Pandey A. Prevalence of MLR blocking antibodies before and after immunotherapy. J Hematother Stem Cell Res 2000;9:257–262. 372. Clark DA, Gorczynski RM, Blajchman MA. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen. Transfusion 2008;48:814–821. 373. Gafter U, Sredni B, Segal J, et al. Suppressed cell-mediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion. J Clin Immunol 1997;17:408–419. 374. Ito K, Tanaka T, Tsutsumi N, et al. Possible mechanisms of immunotherapy for maintaining pregnancy in recurrent spontaneous aborters: analysis of anti-idiotypic antibodies directed against autologous T-cell receptors. Hum Reprod 1999;14:650–655. 375.


Gynecology_Novak

Gynecology_Novak. 375. Prigoshin N, Tambutti ML, Redal MA, et al. Microchimerism and blocking activity in women with recurrent spontaneous abortion (RSA) after alloimmunization with the partner’s lymphocytes. J Reprod Immunol 1999;44:41–54. 376. Adachi H, Takakuwa K, Mitsui T, et al. Results of immunotherapy for patients with unexplained secondary recurrent abortions. Clin Immunol 2003;106:175–180. 377. Daya S, Gunby J. The effectiveness of allogeneic leukocyte immunization in unexplained primary recurrent spontaneous abortion. Recurrent Miscarriage Immunotherapy Trialists Group. Am J Reprod Immunol 1994;32:294–302. 378. Fraser EJ, Grimes DA, Schulz KF. Immunization as therapy for recurrent spontaneous abortion: a review and meta-analysis. Obstet Gynecol 1993;82:854–859. 379. Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet 1985;1:941–943. 380.


Gynecology_Novak

Gynecology_Novak. 379. Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet 1985;1:941–943. 380. Ober C, Karrison T, Odem RR, et al. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet 1999;354:365–369. 381. Porter FT, LaCoursiere Y, Scott RT Jr. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2010;4: CD00. 382. Kling C, Steinmann J, Westphal E, et al. Adverse effects of intra-dermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity. Hum Reprod 2006;21:429–435. 383. Christiansen OB. Intravenous immunoglobulin in the prevention of recurrent spontaneous abortion: the European experience. Am J Reprod Immunol 1998;39:77–81. 384. Hill JA, Anderson DJ. Blood transfusions for recurrent abortion: is the treatment worse than the disease? Fertil Steril 1986;46:152– 154. 385.


Gynecology_Novak

Gynecology_Novak. 384. Hill JA, Anderson DJ. Blood transfusions for recurrent abortion: is the treatment worse than the disease? Fertil Steril 1986;46:152– 154. 385. Hofmeyr GJ, Joffe MI, Bezwoda WR, et al. Immunologic investigation of recurrent pregnancy loss and consequences of immunization with husbands’ leukocytes. Fertil Steril 1987;48:681–684. 386. Katz I, Fisch B, Amit S, et al. Cutaneous graft-versus-host-like reaction after paternal lymphocyte immunization for prevention of recurrent abortion. Fertil Steril 1992;57:927–929. 387. Johnson PM, Ramsden GH. Recurrent miscarriage. Ballieres Clin Immunol Allergy 1992;2:607–624. 388. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2006;2:CD000112. 389. Coulam CB, Stern JJ. Seminal plasma treatment of recurrent spontaneous abortion. In: Dondero F, Johnson PM, eds. Reproductive immunology. Serono Symposia 97. New York: Raven Press, 1993:205–216. 390.


Gynecology_Novak

Gynecology_Novak. 390. Thaler CJ. Immunological role for seminal plasma in insemination and pregnancy. Am J Reprod Immunol 1989;21:147–150. 391. Jerzak M, Rechberger T, Gorski A. Intravenous immunoglobulin therapy inﬂuences T cell adhesion to extracellular matrix in women with a history of recurrent spontaneous abortions. Am J Reprod Immunol 2000;44:336–341. 392. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107–116. 393. Samuelsson A, Towers TL, Ravetch JV. Anti-inﬂammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484–486. 394. Mollnes TE, Hogasen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998;48:312–317. 395. Stephenson MD, Kutteh WH, Purkiss S, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod 2010;25:2203–2209. 396.


Gynecology_Novak

Gynecology_Novak. 396. Jablonowska B, Selbing A, PalfiM, et al. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Hum Reprod 1999;14:838–841. 397. Mueller-Eckhardt G, Heine O, Polten B. IVIG to prevent recurrent spontaneous abortion. Lancet 1991;337:424–425. 398. Perino A, Vassiliadis A, Vucetich A, et al. Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod 1997;12:2388–2392. 399. Stephenson MD, Dreher K, Houlihan E, et al. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: a prospective, randomized, double-blinded, placebo-controlled trial. Am J Reprod Immunol 1998;39:82–88. 400. Harris EN, Pierangeli SS. Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review. Scand J Rheumatol Suppl 1998;107:97–102. 401.


Gynecology_Novak

Gynecology_Novak. 401. Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol 2001;45:174–179. 402. Practice Committee of the American Society for Reproductive Medicine. Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss. Fertil Steril 2006;86(Suppl 4):S226–S227. 403. Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Arch Neurol 1993;50:135–136. 404. Choi BC, Polgar K, Xiao L, et al. Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 2000;15(Suppl 1):46–59. 405. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008;2:CD003511. 406.


Gynecology_Novak

Gynecology_Novak. 405. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008;2:CD003511. 406. Oates-Whitehead RM, Haas DM, Carrier JA. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2003;4: CD003511. 407. Battistella FD, Widergren JT, Anderson JT, et al. A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring total parenteral nutrition. J Trauma 1997;43:52–60. 408. Mayer K, Meyer S, Reinholz-Muhly M, et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinﬂammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol 2003;171:4837–4843. 409. Sedman PC, Somers SS, Ramsden CW, et al. Effects of different lipid emulsions on lymphocyte function during total parenteral nutrition. Br J Surg 1991;78:1396–1399. 410.


Gynecology_Novak

Gynecology_Novak. 409. Sedman PC, Somers SS, Ramsden CW, et al. Effects of different lipid emulsions on lymphocyte function during total parenteral nutrition. Br J Surg 1991;78:1396–1399. 410. Clark DA. Intralipid as treatment for recurrent unexplained abortion? Am J Reprod Immunol 1994;32:290–293. 411. Roussev RG, Acacio B, Ng SC, et al. Duration of intralipid’s suppressive effect on NK cell’s functional activity. Am J Reprod Immunol 2008;60:258–263. 412. Roussev RG, Ng SC, Coulam CB. Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. Am J Reprod Immunol 2007;57:262–269. 413. Arslan E, Colakolu M, Celik C, et al. Serum TNF-alpha, IL-6, lupus anticoagulant and anticardiolipin antibody in women with and without a past history of recurrent miscarriage. Arch Gynecol Obstet 2004;270:227–229. 414.


Gynecology_Novak

Gynecology_Novak. 414. Palmirotta R, La Farina F, Ferroni P, et al. TNFA gene promoter polymorphisms and susceptibility to recurrent pregnancy loss in Italian women. Reprod Sci 2010;17:659–666. 415. Zammiti W, Mtiraoui N, Finan RR, et al. Tumor necrosis factor alpha and lymphotoxin alpha haplotypes in idiopathic recurrent pregnancy loss. Fertil Steril 2009;91:1903–1908. 416. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977–1983. 417. Mossner R, Schon MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol 2008;26:486–502. 418.


Gynecology_Novak

Gynecology_Novak. 417. Mossner R, Schon MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol 2008;26:486–502. 418. Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008;60:8–16. 419. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635– 641. 420. Ferro D, Quintarelli C, Russo G, et al. Successful removal of antiphospholipid antibodies using repeated plasma exchanges and prednisone. Clin Exp Rheumatol 1989;7:103–104. 421. Doss BJ, Greene MF, Hill J, et al. Massive chronic intervillositis associated with recurrent abortions. Hum Pathol 1995;26:1245– 1251. 422.


Gynecology_Novak

Gynecology_Novak. 421. Doss BJ, Greene MF, Hill J, et al. Massive chronic intervillositis associated with recurrent abortions. Hum Pathol 1995;26:1245– 1251. 422. Lubbe WF, Butler WS, Palmer SJ, et al. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet 1983;1:1361–1363. 423. Quenby S, Farquharson R, Young M, et al. Successful pregnancy outcome following 19 consecutive miscarriages: case report. Hum Reprod 2003;18:2562–2564. 424. Quenby S, Kalumbi C, Bates M, et al. Prednisolone reduces preconceptual endometrial natural killer cells in women with recurrent miscarriage. Fertil Steril 2005;84:980–984. 425. Tang AW, Alfirevic Z, Turner MA, et al. Prednisolone Trial: Study protocol for a randomised controlled trial of prednisolone for women with idiopathic recurrent miscarriage and raised levels of uterine natural killer (uNK) cells in the endometrium. Trials 2009;10:102. 426.


Gynecology_Novak

Gynecology_Novak. 426. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;337:148–153. 427. Ermel LD, Marshburn PB, Kutteh WH. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am J Reprod Immunol 1995;33:14– 20. 428. G´orski A, Makula J, Morzycka-Michalik M, et al. Low-dose heparin: a novel approach in immunosuppression. Transpl Int 1994;7(Suppl 1):S567–S569. 429. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584–1589. 430. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14:131–136. 431.


Gynecology_Novak

Gynecology_Novak. 430. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14:131–136. 431. Mak A, Cheung MW, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010;49:281–288. 432. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253–257. 433. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010;115:1256–1262. 434.


Gynecology_Novak

Gynecology_Novak. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010;115:1256–1262. 434. Bates SM, Ginsberg JS. Anticoagulation in pregnancy. Pharm Pract Manag Q 1999;19:51–60. 435. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):844S–886S. 436. Bijsterveld NR, Hettiarachchi R, Peters R, et al. Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost 1999;82(Suppl 1):139–147. 437. Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy—how safe are they? Curr Opin Obstet Gynecol 2007;19:573–577. 438.


Gynecology_Novak

Gynecology_Novak. 437. Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy—how safe are they? Curr Opin Obstet Gynecol 2007;19:573–577. 438. Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004;26:729–734. 439. Bar J, Cohen-Sacher B, Hod M, et al. Low-molecular-weight heparin for thrombophilia in pregnant women. Int J Gynaecol Obstet 2000;69:209–213. 440. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003;1:433–438. 441. Younis JS, Ohel G, Brenner B, et al. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. Bjog 2000;107:415–419. 442.


Gynecology_Novak

Gynecology_Novak. 442. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001;108:1134–1140. 443. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecularweight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668–672. 444. Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000;183:1008–1012. 445. Rai R, Regan L. Thrombophilia and adverse pregnancy outcome. Semin Reprod Med 2000;18:369–377. 446. James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv 2008;63:49–57. 447. Richards EM, Makris M, Preston FE. The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. Br J Haematol 1997;98:660–661.


Gynecology_Novak

Gynecology_Novak. 448. Brouwer IA, van Dusseldorp M, Thomas CM, et al. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Am J Clin Nutr 1999;69:99–104. 449. Carlsson CM, Pharo LM, Aeschlimann SE, et al. Effects of multivitamins and low-dose folic acid supplements on ﬂow-mediated vasodilation and plasma homocysteine levels in older adults. Am Heart J 2004;148: E11. 450. de la Calle M, Usandizaga R, Sancha M, et al. Homocysteine, folic acid and B-group vitamins in obstetrics and gynaecology. Eur J Obstet Gynecol Reprod Biol 2003;107:125–134. 451. O’Donnell J, Perry DJ. Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia. Expert Opin Pharmacother 2002;3:1591–1598. 452. Neugebauer R, Kline J, Shrout P, et al. Major depressive disorder in the 6 months after miscarriage. JAMA 1997;277:383–388. 453.


Gynecology_Novak

Gynecology_Novak. 452. Neugebauer R, Kline J, Shrout P, et al. Major depressive disorder in the 6 months after miscarriage. JAMA 1997;277:383–388. 453. Harger JH, Archer DF, Marchese SG, et al. Etiology of recurrent pregnancy losses and outcome of subsequent pregnancies. Obstet Gynecol 1983;62:574–581. 454. Phung Thi T, Byrd JR, McDonough PG. Etiologies and subsequent reproductive performance of 100 couples with recurrent abortion. Fertil Steril 1979;32:389–395. 455. Vlaanderen W, Treffers PE. Prognosis of subsequent pregnancies after recurrent spontaneous abortion in first trimester. Br Med J (Clin Res Ed) 1987;295:92–93. 456. DeCherney AH, Russell JB, Graebe RA, et al. Resectoscopic management of mullerian fusion defects. Fertil Steril 1986;45:726– 728. 457. March CM, Israel R. Hysteroscopic management of recurrent abortion caused by septate uterus. Am J Obstet Gynecol 1987;156:834– 842. 458.


Gynecology_Novak

Gynecology_Novak. 457. March CM, Israel R. Hysteroscopic management of recurrent abortion caused by septate uterus. Am J Obstet Gynecol 1987;156:834– 842. 458. Colacurci N, De Franciscis P, Mollo A, et al. Small-diameter hysteroscopy with Versapoint versus resectoscopy with a unipolar knife for the treatment of septate uterus: a prospective randomized study. J Minim Invasive Gynecol 2007;14:622–627. 459. Hollett-Caines J, Vilos GA, Abu-Rafea B, et al. Fertility and pregnancy outcomes following hysteroscopic septum division. J Obstet Gynaecol Can 2006;28:156–159. 460. Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992;80:614–620. 461. Lubbe WF, Liggins GC. Role of lupus anticoagulant and autoimmunity in recurrent pregnancy loss. Semin Reprod Endocrinol 1988;6:161–190. 462.


Gynecology_Novak

Gynecology_Novak. 461. Lubbe WF, Liggins GC. Role of lupus anticoagulant and autoimmunity in recurrent pregnancy loss. Semin Reprod Endocrinol 1988;6:161–190. 462. Prakash A, Laird S, Tuckerman E, et al. Inhibin A and activin A may be used to predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2005;83:1758–1763. 463. Pratt DE, Kaberlein G, Dudkiewicz A, et al. The association of antithyroid antibodies in euthyroid nonpregnant women with recurrent first trimester abortions in the next pregnancy. Fertil Steril 1993;60:1001–1005. 464. Laufer MR, Ecker JL, Hill JA. Pregnancy outcome following ultrasound-detected fetal cardiac activity in women with a history of multiple spontaneous abortions. J Soc Gynecol Investig 1994;1:138– 142. 465. Rai RS, Clifford K, Cohen H, et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301–3304. 466.


Gynecology_Novak

Gynecology_Novak. Rai RS, Clifford K, Cohen H, et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301–3304. 466. Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999;14:2868–2871. Jan L. Shifren Isaac Schiff Vasomotor symptoms affect up to 75% of perimenopausal women. Symptoms last for 1 to 2 years after menopause in most women but may continue for 10 years or longer in others. Topical vaginal application of low doses of estrogen is an effective and safe treatment of vaginal dryness, dyspareunia, and some urinary symptoms.


Gynecology_Novak

Gynecology_Novak. Topical vaginal application of low doses of estrogen is an effective and safe treatment of vaginal dryness, dyspareunia, and some urinary symptoms. Counseling women to alter modifiable risk factors is important for the prevention and treatment of osteoporosis. Many women have diets deficient in calcium and vitamin D and will benefit from dietary changes and supplementation. Women should receive 1,000 to 1,500 mg of calcium and 400 to 800 IU of vitamin D daily. Contraindications to hormone therapy use include known or suspected breast or endometrial cancer, undiagnosed abnormal genital bleeding, cardiovascular disease (including coronary heart disease, cerebrovascular disease, and thromboembolic disorders), and active liver or gallbladder disease. Relative contraindications include high-risk states for the above disorders.


Gynecology_Novak

Gynecology_Novak. Menopause, the permanent cessation of menstruation, occurs at a mean age of 51 years. Despite a great increase in the life expectancy of women, the age at menopause remains remarkably constant. A woman in the United States today will live approximately 30 years, or greater than a third of her life, beyond the menopause. The age at menopause appears to be genetically determined and is unaffected by race, socioeconomic status, age at menarche, or number of prior ovulations. Factors that are toxic to the ovary often result in an earlier age of menopause; women who smoke experience an earlier menopause, as do many women exposed to chemotherapy or pelvic radiation (1). Women who had surgery on their ovaries or had a hysterectomy, despite retention of their ovaries, may experience early menopause (2). Premature ovarian insufficiency, defined as menopause before the age of 40 years, occurs in approximately 1% of women. It may be idiopathic or associated with a toxic exposure, chromosomal


Gynecology_Novak

Gynecology_Novak. (2). Premature ovarian insufficiency, defined as menopause before the age of 40 years, occurs in approximately 1% of women. It may be idiopathic or associated with a toxic exposure, chromosomal abnormality, or an autoimmune disorder.


Gynecology_Novak

Gynecology_Novak. Although menopause is associated with changes in the hypothalamic and pituitary hormones that regulate the menstrual cycle, menopause is not a central event, but rather primary ovarian failure. At the level of the ovary, there is a depletion of ovarian follicles, most likely secondary to apoptosis or programmed cell death. The ovary, therefore, is no longer able to respond to the pituitary hormones, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), and ovarian estrogen and progesterone production ceases. The ovarian–hypothalamic– pituitary axis remains intact during the menopausal transition; thus, FSH levels rise in response to ovarian failure and the absence of negative feedback from the ovary. Atresia of the follicular apparatus, in particular the granulosa cells, leads to decreased production of estrogen and inhibin, resulting in elevated FSH levels, a cardinal sign of menopause. Antim¨ullerian hormone (AMH) is produced by small ovarian follicles, so levels


Gynecology_Novak

Gynecology_Novak. leads to decreased production of estrogen and inhibin, resulting in elevated FSH levels, a cardinal sign of menopause. Antim¨ullerian hormone (AMH) is produced by small ovarian follicles, so levels decrease with declining ovarian reserve (3). Although still considered experimental, AMH may one day be used as a reliable marker of the menopause transition.


Gynecology_Novak

Gynecology_Novak. Androgen production from the ovary continues beyond the menopausal transition because of sparing of the stromal compartment. Androgen concentrations are lower in menopausal women than in women of reproductive age. This finding appears to be associated with aging and decreased functioning of the ovary and adrenal glands over time rather than with menopause per se. Menopausal women continue to have low levels of circulating estrogens, principally from peripheral aromatization of ovarian and adrenal androgens. Adipose tissue is a major site of aromatization, so obesity affects many of the sequelae of menopause. Several staging systems were developed to describe the many changes that encompass the transition from reproductive life to postmenopause. The late reproductive years are characterized by regular menses associated with elevated FSH levels (4).


Gynecology_Novak

Gynecology_Novak. Menopausal transition is characterized by elevated FSH levels associated with variable cycle lengths and missed menses, whereas the postmenopausal period is marked by amenorrhea. The menopausal transition begins with variability in menstrual cycle length accompanied by rising FSH levels and ends with the final menstrual period. Menopause is defined retrospectively as the time of the final menstrual period followed by 12 months of amenorrhea Postmenopause describes the period following the final menses (4).


Gynecology_Novak

Gynecology_Novak. Menopause is defined retrospectively as the time of the final menstrual period followed by 12 months of amenorrhea Postmenopause describes the period following the final menses (4). The pathophysiologic consequences of menopause may be best understood by considering that the ovary is a women’s only source of oocytes, her primary source of estrogen and progesterone, and a major source of androgens. Menopause results in infertility secondary to oocyte depletion. Ovarian cessation of progesterone production appears to have no clinical consequences except for the increased risk of endometrial proliferation, hyperplasia, and cancer associated with continued endogenous estrogen production or administration of unopposed estrogen therapy in menopausal women. The possible effects of declining androgen concentrations that occur with aging are an area of controversy and active investigation.


Gynecology_Novak

Gynecology_Novak. The major consequences of menopause are related primarily to estrogen deficiency. It is very difficult to distinguish the consequences of estrogen deficiency from those of aging, as aging and menopause are inextricably linked. Studying the effects of estrogen deficiency and replacement in young women with ovarian failure or of drugs that suppress estrogen synthesis (such as gonadotropin-releasing hormone antagonists) helps to distinguish between the effects of aging and estrogen deficiency. These models are imperfect, though, and differ from natural menopause in many ways.


Gynecology_Novak

Gynecology_Novak. Principal health concerns of menopausal women include vasomotor symptoms, urogenital atrophy, osteoporosis, cardiovascular disease, cancer, cognitive decline, and sexual problems. Options for caring for menopausal women have increased greatly since hormone therapy was first introduced in the 1960s. With respect to hormone use, there are many choices of hormone type, dose, and method of administration. In addition to hormones, estrogen agonistantagonists, centrally acting agents, and bisphosphonates are available to treat menopausal health concerns. Women are requesting more information on complementary and alternative therapies, which are being studied more carefully. The many options now available make caring for the postmenopausal woman more challenging and more rewarding.


Gynecology_Novak

Gynecology_Novak. Vasomotor symptoms affect up to 75% of perimenopausal women. Symptoms last for 1 to 2 years after menopause in most women, but may continue for up to 10 years or longer in others. Hot ﬂashes are the primary reason women seek care at menopause. Hot ﬂashes disturb women at work, interrupt daily activities and disrupt sleep (5). Many women report difficulty concentrating and emotional lability during the menopausal transition. Treatment of vasomotor symptoms should improve these cognitive and mood symptoms if they are secondary to sleep disruption and its resulting daytime fatigue. The incidence of thyroid disease increases as women age; therefore, thyroid function tests should be performed if vasomotor symptoms are atypical or resistant to therapy.


Gynecology_Novak

Gynecology_Novak. The physiologic mechanisms underlying hot ﬂashes are incompletely understood. A central event, probably initiated in the hypothalamus, drives an increased core body temperature, metabolic rate, and skin temperature; this reaction results in peripheral vasodilation and sweating in some women. The central event may be triggered by noradrenergic, serotoninergic, and/or dopaminergic activation. Although an LH surge often occurs at the time of a hot ﬂash, it is not causative, because vasomotor symptoms occur in women who had their pituitary glands removed. In symptomatic postmenopausal women, hot ﬂashes likely are triggered by small elevations in core body temperature acting within a narrow thermoneutral zone (6). Exactly how estrogen and alternative therapies play a role in modulating these events is unknown. Vasomotor symptoms are a consequence of estrogen withdrawal, not simply estrogen deficiency. For example, a young woman with primary ovarian insufficiency resulting from Turner


Gynecology_Novak

Gynecology_Novak. events is unknown. Vasomotor symptoms are a consequence of estrogen withdrawal, not simply estrogen deficiency. For example, a young woman with primary ovarian insufficiency resulting from Turner syndrome will have a very high FSH level and low estrogen levels, but she will not experience hot ﬂashes until she is treated with estrogens and then therapy is withdrawn.


Gynecology_Novak

Gynecology_Novak. Lifestyle interventions may safely decrease vasomotor symptoms. Being in a cool environment is associated with fewer subjective and objective hot ﬂashes, so women experiencing symptoms should be advised to keep the room temperature low and wear light, layered clothing (7). Overweight women and those who smoke have more severe vasomotor symptoms than women of normal weight and nonsmokers. These findings provide additional reasons to encourage women to lose weight and stop smoking (8,9).


Gynecology_Novak

Gynecology_Novak. Many menopausal women are interested in trying complementary and alternative (CAM) therapies for relief of hot ﬂashes. These are diverse medical and health care products and practices generally not considered part of conventional medicine. Vasomotor symptoms are particularly sensitive to placebo treatments, and numerous nutritional supplements and other interventions claim to relieve hot ﬂashes but are rarely studied in controlled trials (10). Phytoestrogens are plant-derived substances that may act as estrogen agonists-antagonists, with their effects modulated through interactions with the estrogen receptor. Although they decrease hot ﬂash severity and frequency, symptom improvement is similar to that seen with placebo treatment (11). Black cohosh is another popular alternative treatment, with efficacy likely similar to that of placebo (12). Although often recommended, vitamin E (800 IU per day) only minimally reduced hot ﬂashes in a placebo-controlled, randomized, crossover trial


Gynecology_Novak

Gynecology_Novak. with efficacy likely similar to that of placebo (12). Although often recommended, vitamin E (800 IU per day) only minimally reduced hot ﬂashes in a placebo-controlled, randomized, crossover trial (13).


Gynecology_Novak

Gynecology_Novak. Acupuncture reduced vasomotor symptoms in several studies, although a traditional Chinese medicine approach may be no more effective than shallow or “sham” needling techniques (14). Exercise and paced respiration demonstrated an improvement in hot ﬂashes in several uncontrolled studies, with additional health benefits, including stress reduction. Women may choose to use alternative and complementary therapies for relief of symptoms, but they should be aware that the safety and efficacy of these approaches often are unproven.


Gynecology_Novak

Gynecology_Novak. Systemic estrogen therapy is the most effective treatment for vasomotor symptoms and the only therapy currently approved by the U.S. Food and Drug Administration (FDA) for this indication (see Table 34.1 for available hormone therapy formulations). Although standard doses are usually effective, younger women and those with recent oophorectomy may require higher doses. Healthy, nonsmoking women in the perimenopausal transition who are experiencing bothersome hot ﬂashes but still menstruating may benefit from oral contraceptives. The supraphysiologic doses of estrogens and progestins in oral contraceptives effectively treat vasomotor symptoms and provide cycle control. Low-dose estrogen therapy Table 34.1 Hormone Therapy Options Table 34.1 Continued 17β-estradiol (E) + levonorgestrel (P) Climara Pro 0.045 mg E + 0.0015 mg P once weekly


Gynecology_Novak

Gynecology_Novak. Table 34.1 Hormone Therapy Options Table 34.1 Continued 17β-estradiol (E) + levonorgestrel (P) Climara Pro 0.045 mg E + 0.0015 mg P once weekly E, estrogen; P, progestin. Products available in the United States. Table modified and used with permission; North American Menopause Society; www.menopause.org. also effectively treats hot ﬂashes for many women. Low-dose oral esterified and conjugated estrogens (CE) (0.3 mg daily), oral estradiol (0.5 mg daily), and transdermal estradiol (0.025 and 0.014 mg weekly) often are effective and associated with minimal side effects and endometrial stimulation (15–17). Progestin therapy must be given concurrently if a woman has not had a hysterectomy, although with low-dose estrogen therapy, intermittent progestin treatment may be an option.


Gynecology_Novak

Gynecology_Novak. Given the known risks, described in detail later in this chapter, hormone therapy should be used at the lowest effective dose for the shortest amount of time that meets treatment goals. The majority of healthy women with very bothersome hot ﬂashes at the time of the menopausal transition will benefit from short-term therapy and be able to wean off hormones after several years of use.


Gynecology_Novak

Gynecology_Novak. Because vasomotor symptoms appear to be the result of estrogen withdrawal, rather than simply low estrogen levels, if cessation of estrogen therapy is desired, the dose should be reduced slowly over time. Abruptly stopping treatment may result in a return of disruptive vasomotor symptoms. This recommendation is based on clinical experience, as no controlled trials have been performed to examine the optimal way to cease hormone therapy use. One possible approach to stopping therapy is to reduce the dose and dosing interval slowly (e.g., every 2 or 3 months) and let the patient’s symptoms guide the pace at which she discontinues therapy.


Gynecology_Novak

Gynecology_Novak. When a woman chooses not to take estrogen or when it is contraindicated, other options are available (Table 34.2) (18). Progestin therapy alone is an option for some women. Medroxyprogesterone acetate (MPA; Provera) (20 mg per day) and megestrol acetate (Megace) (20 mg per day) effectively treat vasomotor symptoms (19,20). Several drugs that alter central neurotransmitter pathways are effective. Agents that decrease central noradrenergic tone, such as clonidine (Catapres), decrease hot ﬂashes, although the effect size is not great. Potential side effects include orthostatic hypotension and drowsiness.


Gynecology_Novak

Gynecology_Novak. Selective serotonin or serotonin norepinephrine reuptake inhibitors (SSRIs/SNRIs) are effective and are the mainstay of nonhormonal treatment of hot ﬂashes, although none are FDA approved for this purpose. In a double-blind, randomized, placebo-controlled trial of paroxetine CR (Paxil) (12.5 and 25 mg per day), menopausal women with hot ﬂashes experienced a significant reduction in both hot ﬂash frequency and severity (21). Actual hot ﬂash frequency decreased by 3.3 hot ﬂashes per day on paroxetine versus 1.8 on placebo, and the improvement in Table 34.2 Options for the Treatment of Vasomotor Symptoms aNot U.S. Food and Drug Administration–approved for treatment of vasomotor symptoms.


Gynecology_Novak

Gynecology_Novak. vasomotor symptoms was independent of any significant change in mood or anxiety symptoms. The most common side effects were headache, nausea, and insomnia. Paroxetine is a potent inhibitor of the cytochrome P450 system (CYP2D6) required to convert tamoxifen to its active form. It should not be used in women with breast cancer who are receiving tamoxifen, as concurrent use may result in a higher rate of breast cancer recurrence. Venlafaxine (Effexor) (75 mg per day), an SNRI, significantly reduced hot ﬂashes in a controlled trial, though the active treatment group experienced significantly more side effects, including dry mouth, nausea, and anorexia (22). Most studies of SSRI or SNRI use for vasomotor symptoms are only short term and not all show an improvement in symptoms. In a double-blind, parallel-group trial of 9 months’ duration, there was no significant improvement in hot ﬂashes with either ﬂuoxetine (Prozac) or citalopram (Celexa) (10 to 30 mg per day) compared to placebo (23).


Gynecology_Novak

Gynecology_Novak. Gabapentin (Neurontin)isa γ-aminobutyric acid analogue approved for the treatment of seizures that reduced hot ﬂash frequency and severity significantly more than placebo in several randomized, double-blind trials (24). Hot ﬂash scores decreased 54% in the women treated with gabapentin (900 mg per day) compared with a 31% reduction in placebo-treated women. Side effects include disorientation, dizziness, and drowsiness. Women who are principally bothered by night sweats and disrupted sleep may benefit from sleeping medication. In a double-blind, placebo-controlled study of peri-and postmenopausal women, the prescription insomnia treatment, eszopiclone, significantly improved sleep and menopause-related symptoms, with a positive impact on next-day functioning, mood, and quality of life (25). The antihistamine diphenhydramine hydrochloride is an inexpensive, over-the-counter sleep aid.


Gynecology_Novak

Gynecology_Novak. Urogenital Atrophy Urogenital atrophy results in vaginal dryness and pruritus, dyspareunia, dysuria, and urinary urgency. These common problems in menopausal women respond well to therapy (26). Systemic estrogen therapy is a very effective treatment for vaginal dryness, dyspareunia, and associated symptoms. Low doses of estrogen applied vaginally are preferred to systemic estrogen therapy when vasomotor symptoms are not present, given minimal systemic absorption and increased safety. Low doses of estrogen cream (Premarin, Estrace) (0.5 g) are effective when used only once or twice a week (27). An estradiol vaginal tablet (Vagifem) (10 μg) inserted twice weekly may be less messy and easier to use than estrogen cream. An estrogen-containing vaginal ring (Estring) (7.5 μg per day) is another convenient formulation, which is placed in the vagina every 3 months and slowly releases a low dose of estradiol (28). Studies of the low-dose estrogen vaginal ring and tablet confirm a small


Gynecology_Novak

Gynecology_Novak. another convenient formulation, which is placed in the vagina every 3 months and slowly releases a low dose of estradiol (28). Studies of the low-dose estrogen vaginal ring and tablet confirm a small increase in serum estradiol and estrone levels, but these levels remain within the normal range for postmenopausal women (29).


Gynecology_Novak

Gynecology_Novak. Studies of the vaginal tablets and ring of up to 1 years’ duration confirmed endometrial safety, but long-term studies on the effects of low-dose vaginal estrogen therapy on the endometrium are not available. Women using vaginal estrogen therapy should be reminded to report any vaginal bleeding, and a thorough evaluation should be performed. Typically, concurrent progestin therapy is not prescribed with low-dose vaginal estrogen preparations. Long-acting vaginal moisturizers, available without a prescription, are an effective nonhormonal alternative for treating symptoms of urogenital atrophy when used two to three times weekly (e.g., Replens, KY-Long Acting). Nonhormonal vaginal lubricants (e.g., Astroglide, KY-Silk) increase comfort with intercourse.


Gynecology_Novak

Gynecology_Novak. Vaginal estrogen therapy appears to reduce urinary symptoms, such as frequency and urgency, and reduces the likelihood of recurrent urinary tract infections in postmenopausal women (30). The effect of estrogen therapy on urinary incontinence is unclear. Whereas the results of some studies suggest improvement in incontinence with estrogen therapy, others show a worsening of symptoms (31).


Gynecology_Novak

Gynecology_Novak. Osteoporosis Low bone mass and osteoporosis affect an estimated 30 million US women, or approximately 55% of women older than age 50 years (32). Because therapy is most likely to benefit those at highest risk, it is important to review a woman’s risk factors for osteoporosis when making treatment decisions. Bone mineral density screening should be considered for high-risk women (Table 34.3). Nonmodifiable risk factors include age, family history, Asian or Caucasian race, history of a prior fracture, small body frame, early menopause, and prior oophorectomy. Modifiable risk factors include smoking, decreased intake of calcium and vitamin D, and a sedentary lifestyle. Medical conditions associated with an increased risk of Table 34.3 Risk Factors for Osteoporosis Age Race (white, Asian) Small body frame Family history of osteoporosis


Gynecology_Novak

Gynecology_Novak. Table 34.3 Risk Factors for Osteoporosis Age Race (white, Asian) Small body frame Family history of osteoporosis Inadequate intake of calcium and vitamin D Smoking osteoporosis include anovulation during the reproductive years (e.g., secondary to excess exercise or an eating disorder), chronic renal disease, hyperparathyroidism, hyperthyroidism, and diseases requiring systemic corticosteroid use. Table 34.4 Options for Osteoporosis Prevention and Treatment Additional potential benefits: none Potential risks: esophageal ulcers, osteonecrosis of jaw (rare), atypical femoral fractures (rare) Zoledronic acid: hypocalcemia, atrial fibrillation, renal impairment Side effects: gastrointestinal distress, arthralgias/myalgias Additional potential benefits: treatment of vasomotor symptoms and urogenital atrophy Potential risks: breast cancer, gallbladder disease, venous thromboembolic events, coronary heart disease, stroke Side effects: vaginal bleeding, breast tenderness


Gynecology_Novak

Gynecology_Novak. Side effects: vaginal bleeding, breast tenderness Additional potential benefits: reduced risk of breast cancer Potential risks: venous thromboembolic events Side effects: vasomotor symptoms, leg cramps Additional potential benefits: none Potential risks: none Side effects: rhinitis, back pain Additional potential benefits: none Potential risks: osteosarcoma (after long-term use in rodents), hypercalcemia Side effects: musculoskeletal pain Additional potential benefits: none Potential risks: rash, serious infection, hypocalcemia


Gynecology_Novak

Gynecology_Novak. Additional potential benefits: none Potential risks: rash, serious infection, hypocalcemia Side effects: musculoskeletal pain osteoporosis-related fractures by approximately 50% (39). The Women’s Health Initiative (WHI) trial confirmed a significant (34%) reduction in hip fractures in healthy women randomized to hormone therapy (conjugated estrogen 0.625 mg per day) after a mean follow-up of 5.6 years (40). Combined with calcium and vitamin D, even very low-dose estrogen therapy (conjugated estrogen 0.3 mg per day; transdermal estradiol 0.014 mg per day) produces significant increases in bone mineral density compared with placebo (41).


Gynecology_Novak

Gynecology_Novak. Bisphosphonates, including alendronate (Fosamax, 35 or 70 mg orally weekly), risedronate (Actonel, 35 mg weekly or 150 mg orally monthly), ibandronate (Boniva, 150 mg orally monthly or 3 mg every 3 months intravenous), and zoledronic acid (Zometa, 5 mg intravenous yearly) specifically inhibit bone resorption and are very effective for both the prevention and treatment of osteoporosis (42–44). Patients should take oral bisphosphonates on an empty stomach with a large glass of water and remain upright for at least 30 minutes. The major side effect is gastrointestinal distress; esophageal ulceration, osteonecrosis of the jaw, and atypical femoral fractures are very rare occurrences.


Gynecology_Novak

Gynecology_Novak. The estrogen agonist-antagonist raloxifene (Evista, 60 mg per day orally) prevents vertebral fractures in women with low bone mass and osteoporosis, though does not appear to reduce the risk of nonvertebral fractures (45). Raloxifene exercises estrogen-like actions on bone and lipids without stimulating the breast or endometrium. Calcitonin nasal spray (Miacalcin, 200 IU per day intranasal) is another approved treatment for established osteoporosis. Unlike most treatments for osteoporosis that inhibit bone resorption, parathyroid hormone (human recombinant PTH 1–34) (teriparatide, Forteo, 20 μg per day subcutaneously) stimulates new bone formation, resulting in significant reductions in vertebral and nonvertebral fractures (46). Recently approved for the treatment of postmenopausal osteoporosis, denosumab (Prolia) 60 mg, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand, decreases the risk of vertebral and hip fractures in postmenopausal osteoporotic women


Gynecology_Novak

Gynecology_Novak. denosumab (Prolia) 60 mg, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand, decreases the risk of vertebral and hip fractures in postmenopausal osteoporotic women when given subcutaneously twice yearly for 36 months’ duration (47).


Gynecology_Novak

Gynecology_Novak. Cardiovascular Disease Cardiovascular disease (CVD) is the leading cause of death for women, accounting for approximately 45% of mortality. Nonmodifiable risk factors include family history and age. Modifiable risk factors include a sedentary lifestyle, obesity, and smoking. Medical conditions associated with an increased risk of heart disease include diabetes, hypertension, and hyperlipidemia. Advising women to alter modifiable risk factors for CVD and adequately treating diabetes, hypertension, and hyperlipidemia are important parts of the comprehensive care of midlife women.


Gynecology_Novak

Gynecology_Novak. As epidemiologic studies identify an approximately 50% decrease in coronary heart disease (CHD) in woman who use hormone therapy, prevention of heart disease was considered a potential benefit of postmenopausal hormones (48). This observed reduction in CHD was considered secondary to beneficial effects of hormone therapy on the vascular wall and lipid levels (49). Observational studies are prone to bias, and women who used hormone therapy were generally healthier and at lower risk for CHD than nonusers (50).


Gynecology_Novak

Gynecology_Novak. The WHI randomized controlled trial of combination hormone therapy versus placebo showed that hormone therapy did not prevent heart disease in healthy women, but instead, it increased the risk of cardiovascular events in older women (51). The WHI was a 15-year study sponsored by the National Institutes of Health that examined ways to prevent heart disease, osteoporosis, and breast and colorectal cancer in women. There were several different studies in WHI, involving more than 160,000 healthy postmenopausal women. The WHI randomized controlled trial enrolled approximately 16,000 women nationwide between the ages of 50 and 79 years. The average age of women in the study was 63 years. The major goal of the WHI clinical trial was to determine whether combined estrogen and progestin hormone therapy prevented heart disease and to evaluate associated benefits and risks. After an average of 5 years of follow-up, risks (hazard ratio) were increased for CHD (1.3), breast cancer (1.3), stroke


Gynecology_Novak

Gynecology_Novak. therapy prevented heart disease and to evaluate associated benefits and risks. After an average of 5 years of follow-up, risks (hazard ratio) were increased for CHD (1.3), breast cancer (1.3), stroke (1.4), and pulmonary embolism (PE) (2.1), and decreased for hip fracture (0.7) and colorectal cancer (0.6) (51). The absolute excess risk per 10,000 woman-years attributable to hormone therapy was small, with seven more CHD events, eight breast cancers, eight strokes, and eight pulmonary embolisms, with six fewer colorectal cancers and five fewer hip fractures.


Gynecology_Novak

Gynecology_Novak. Approximately 11,000 women without a uterus participated in a separate WHI study and were randomized either to estrogen alone or placebo. After an average follow-up of 7 years, there was no increased risk of heart disease or breast cancer in estrogen users. Outcomes were similar to those seen in the estrogen plus progestin arm of WHI with respect to venous thromboembolism, stroke, and osteoporotic fractures; there was no effect on colorectal cancer (52) (see Table 34.5 for a summary of WHI findings).


Gynecology_Novak

Gynecology_Novak. Studies confirmed that the increased risk of CHD in WHI occurs principally in older women and those who are a number of years beyond menopause (Table 34.6). In a secondary analysis of data from the combined WHI trials, no increased risk of CHD was seen in women between the ages 50 to 59 or in those within 10 years of menopause (53). Although stroke was increased with hormone therapy, regardless of age or years since menopause, the absolute excess risk of stroke in the younger women was minimal. These data do not support a Table 34.5 Summary of Women’s Health Initiative Study Results Risks per 10,000 Woman-Years Attributable to Estrogen Plus Progestin a Risks per 10,000 Woman-Years Attributable to Estrogen Alone (Hysterectomized Women)b


Gynecology_Novak

Gynecology_Novak. Risks per 10,000 Woman-Years Attributable to Estrogen Plus Progestin a Risks per 10,000 Woman-Years Attributable to Estrogen Alone (Hysterectomized Women)b WHIMS, Women’s Health Initiative Memory Study. a From Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333; and Shumaker S, Legault C, Rapp S, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA 2003;289:2651–2662. bFrom Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701–1712. Table 34.6 Absolute Excess Risk of Coronary Heart Disease and Mortality


Gynecology_Novak

Gynecology_Novak. Table 34.6 Absolute Excess Risk of Coronary Heart Disease and Mortality Absolute excess risk of coronary heart disease and mortality (cases per 10,000 woman-years) by age and years since menopause in the combined trials (estrogen + progestin and estrogen alone) of the WHI. (Rossouw J, Prentice R, Manson J, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–1477). aP = .03 compared with age 50–59 years or less than 10 years since menopause. bGlobal index is a composite of coronary heart disease, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer, hip fracture, and mortality. From Martin K, Manson J. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 2008;93:4567–4575. Copyright 2008, The Endocrine Society.


Gynecology_Novak

Gynecology_Novak. role for hormone therapy in the prevention of heart disease, but they do provide reassurance regarding the safety of hormone therapy use for bothersome hot ﬂashes and night sweats in otherwise healthy women at the time of the menopausal transition. The WHI trials examined treatment only with conjugated equine estrogens and medroxyprogesterone acetate. The effects of other oral estrogen agents, transdermal estradiol, therapy with other progestins, or cyclic hormone therapy may be different. In observational studies, transdermal estrogen therapy is not associated with an increased risk of venous thromboembolic disease (54). The average age of women participating in these trials was more than 15 years beyond the age at which women typically initiate hormone therapy for the treatment of vasomotor symptoms. It is possible that early initiation of hormone therapy may result in a more favorable risk–benefit profile.


Gynecology_Novak

Gynecology_Novak. The effects of the estrogen agonist-antagonist raloxifene on CHD was studied in a multicenter, randomized trial of approximately 10,000 older postmenopausal women with heart disease or multiple risk factors. Compared with placebo, raloxifene had no significant effect on death from any cause, coronary events, or total stroke, though risk of fatal stroke and venous thromboembolic disease was increased (55). The risks of clinical vertebral fractures and invasive breast cancer were significantly reduced.


Gynecology_Novak

Gynecology_Novak. Breast Cancer Breast cancer is a major health concern for menopausal women, as it is the most common cancer in women and the second leading cause of cancer death (56). The lifetime risk of invasive breast cancer for US women is 12%; therefore, any therapies that increase or reduce this risk will have a major impact on women’s health. Risk factors for breast cancer include age, family history, early menarche, late menopause, and prior breast disease, including epithelial atypia and cancer. Risk is reduced in women who had bilateral oophorectomy or a term pregnancy before the age of 30. Many of these risk factors are consistent with the hypothesis that prolonged estrogen exposure increases breast cancer risk.


Gynecology_Novak

Gynecology_Novak. Long-term use of hormone therapy, generally defined as greater than 5 years, is associated with an increased risk of breast cancer (relative risk [RR] = 1.3) in observational studies (57). There is no increased risk of breast cancer in past users of hormone therapy. The results of several studies suggest that the risk of breast cancer associated with the use of estrogen alone may be lower, with a higher risk in users of estrogen plus progestin (58). The WHI randomized controlled trial demonstrated a significant (26%) increase in the risk of invasive breast cancer after approximately 5 years of use of hormone therapy (51). In women with a prior hysterectomy, there was no increased risk of breast cancer after an average of 7 years of use of estrogen alone (52).


Gynecology_Novak

Gynecology_Novak. Hormone therapy should not be prescribed to women with a history of breast cancer and should be used by women at high risk only after a very careful assessment of potential benefits and risks. A randomized trial of hormone therapy use in women with a history of breast cancer and bothersome hot ﬂashes was stopped after only 2 years, as more new breast cancers were diagnosed in woman randomized to hormone therapy (59).


Gynecology_Novak

Gynecology_Novak. The estrogen agonist-antagonist tamoxifen (Nolvadex, 20 mg per day orally) is used in the treatment of estrogen-receptor positive breast cancer. Both tamoxifen and raloxifene reduce the risk of breast cancer in high-risk women by approximately 50% and are approved for this indication (60). The risk of venous thromboembolism is increased approximately threefold with the use of tamoxifen and raloxifene, similar to the increase seen with hormone therapy. Tamoxifen acts as an estrogen agonist in the endometrium, increasing the risk of endometrial polyps, hyperplasia, and cancer, whereas no endometrial stimulation is seen with raloxifene. Performing a screening mammography examination annually for women older than age 50 years reduces breast cancer mortality. Monthly breast self-examination is advised.


Gynecology_Novak

Gynecology_Novak. Alzheimer’s Disease Alzheimer’s disease is the most common form of dementia. Women are at greater risk for developing the disease than men, and the number of affected individuals in the United States is estimated to be more than 5 million with an annual cost of 183 billion dollars. Although several small studies suggest that hormone therapy may decrease the risk of Alzheimer’s disease, a randomized controlled study in women with mild to moderate Alzheimer’s disease showed that 1 year of estrogen therapy neither slowed disease progression nor improved cognition (61). The WHI Memory Study (WHIMS) was a randomized placebo-controlled study of women aged 65 years or older enrolled in WHI, which assessed the effect of hormone therapy on cognitive function. In contrast to observational studies, women in WHIMS randomized to hormone therapy experienced a significant twofold increased risk of dementia, most commonly Alzheimer’s disease (62). Hormone therapy use was associated with an adverse


Gynecology_Novak

Gynecology_Novak. women in WHIMS randomized to hormone therapy experienced a significant twofold increased risk of dementia, most commonly Alzheimer’s disease (62). Hormone therapy use was associated with an adverse effect on cognition, as women randomized to hormone therapy scored significantly lower on the Modified Mini-Mental State Examination compared with placebo-treated women (63). Given the increased incidence of stroke identified in hormone therapy users in the WHI trial, it is possible that small, undetected cerebrovascular events were more likely to occur in the hormone therapy group, increasing the risk of dementia.


Gynecology_Novak

Gynecology_Novak. For a healthy woman with bothersome hot ﬂashes, hormone therapy remains a very reasonable option, especially if she is within 10 years of menopause or less than age 60. Hormone therapy should be used at the lowest effective dose for the shortest duration consistent with treatment goals (64–66). The need for continued hormone therapy use should be assessed at least annually.


Gynecology_Novak

Gynecology_Novak. The use of unopposed estrogen is associated with an increased risk of endometrial hyperplasia and cancer. Therefore, combination estrogen-progestin therapy is recommended for all women with a uterus. Treatment may be provided in a sequential manner, with estrogen daily and progestin for 12 to 14 days of each month, or in a continuous-combined fashion with estrogen and a lower dose of progestin daily. Sequential regimens result in regular, predictable vaginal bleeding. The majority of women using continuous-combined regimens will experience amenorrhea by the end of 1 year of therapy, but the bleeding that does occur is irregular and unpredictable. Low-dose combination hormone therapy products (e.g., Prempro 0.45/1.5 and 0.3/1.5 mg per day) generally result in a lower incidence of breakthrough bleeding and breast tenderness (67).


Gynecology_Novak

Gynecology_Novak. Women using low doses of oral or transdermal estrogens may elect intermittent progestin use (e.g., 14 days every 3 to 4 months) (68), although these are not approved regimens. A progestincontaining intrauterine device approved for contraception in premenopausal women provides endometrial protection in estrogen-treated menopausal women, although it is not approved for this indication (69). Increased endometrial surveillance is advised with these alternative regimens.


Gynecology_Novak

Gynecology_Novak. Transdermal administration of estradiol with a patch, spray, or gel may be preferred by some women. Avoiding the “first pass hepatic effect” of oral estrogens on lipids, binding globulins and clotting factors may have benefits for women on thyroid replacement or those with low libido (70). In contrast to oral administration, transdermal estradiol does not appear to increase the risk of venous thromboembolic events or gallbladder disease, though it remains contraindicated in women at high risk for venous thromboembolic disease or those with active liver or gallbladder disease.


Gynecology_Novak

Gynecology_Novak. Popularized by the media, many women are interested in using “bioidentical hormones” for treatment of menopausal symptoms. Bioidentical generally refers to hormones structurally identical to “natural” hormones made by the ovary, including estradiol and progesterone. FDA-approved oral and transdermal estradiol products are available in a wide range of doses, as is an oral form of micronized progesterone (Prometrium, 100 to 200 mg per day). Progesterone should be taken at bedtime, as it may cause drowsiness. There is potentially significant increased risk and no known benefit to the use of custom-compounded bioidentical hormone therapy formulations, preparations that are “custom” mixed and packaged by a compounding pharmacist for an individual patient (see Table 34.1 for approved hormone therapy formulations).


Gynecology_Novak

Gynecology_Novak. Contraindications to hormone therapy use include known or suspected breast or endometrial cancer, undiagnosed abnormal genital bleeding, cardiovascular disease (including coronary heart disease, cerebrovascular disease, and thromboembolic disorders), and active liver or gallbladder disease. Relative contraindications include high-risk states for the above disorders. These situations require a thoughtful assessment of potential risks and benefits and documentation of informed patient consent before treatment.


Gynecology_Novak

Gynecology_Novak. Sexual problems are highly prevalent, reported in approximately 40% of US women, with 12% reporting a sexual problem associated with personal distress (71). Although sexual problems generally increase with aging, distressing sexual problems peak in midlife women (aged 45 to 64) and are lowest in women 65 years or older. The etiology of female sexual dysfunction is often multifactorial, including depression or anxiety, relationship conﬂict, stress, fatigue, prior abuse, medications, or physical problems that make sexual activity uncomfortable, such as endometriosis or atrophic vaginitis. The impact of the menopausal transition on sexual function was examined in a prospective, longitudinal cohort study of approximately 3,000 women who were pre-or perimenopausal at baseline and followed for 6 years. Pain during sexual intercourse increased and sexual desire decreased over the menopausal transition, but other factors were unaffected, including sexual arousal, frequency, and pleasure (72).


Gynecology_Novak

Gynecology_Novak. years. Pain during sexual intercourse increased and sexual desire decreased over the menopausal transition, but other factors were unaffected, including sexual arousal, frequency, and pleasure (72). In contrast to menopausal factors, which were unrelated to most aspects of sexual functioning, age, social, health, and psychological factors were strongly linked.


Gynecology_Novak

Gynecology_Novak. Hormone Therapy Estrogen therapy is very effective in treating vaginal dryness and dyspareunia; however, a significant effect of estrogen therapy on sexual interest, arousal, and orgasmic response, independent from its role in treating menopausal symptoms, is not supported by evidence. A woman with distressing low libido concurrent with the onset of bothersome night sweats, sleep disruption, and fatigue likely will experience increased sexual interest with effective treatment of her menopausal symptoms, but this is probably secondary to improved well-being, rather than a direct effect of estrogen therapy on libido. A double-blind, randomized trial of combined oral and vaginal estrogen therapy in 285 sexually active postmenopausal women demonstrated decreased dyspareunia and significant improvements in pleasure of orgasm and sexual interest in women treated with estrogen therapy compared to placebo (73). As this trial used a combination of systemic and vaginal estrogens, it is not


Gynecology_Novak

Gynecology_Novak. improvements in pleasure of orgasm and sexual interest in women treated with estrogen therapy compared to placebo (73). As this trial used a combination of systemic and vaginal estrogens, it is not possible to determine the relative impact of systemic versus local effects.


Gynecology_Novak

Gynecology_Novak. In contrast to estrogen therapy, androgen therapy is consistently shown to improve sexual function in selected populations of postmenopausal women (74–76). Potential risks of androgen therapy include hirsutism, acne, irreversible deepening of the voice, and adverse changes in liver function and lipids. As most androgens are aromatized to estrogens, there is potential for an increased risk of cardiovascular events or breast cancer. A transdermal testosterone patch is approved in Europe for the treatment of hypoactive sexual desire disorder in surgically post-menopausal women using concomitant estrogen therapy. An advisory panel of the FDA did not recommend approval in the United States pending additional data on long-term safety. Alternatives to Hormone Therapy


Gynecology_Novak

Gynecology_Novak. Although vaginal atrophy and dyspareunia respond very well to estrogen therapy, most other sexual problems may be effectively treated without hormones. Relationship quality and conﬂict, stress, and fatigue predict sexual satisfaction, so couples often benefit from counseling, lifestyle changes, and prescribed “date nights.” Women and their partners should be referred to sex therapists who provide education, materials, counseling, and instruction in specific exercises (77). In one study, 65% of 365 couples undergoing sex therapy for a range of sexual dysfunctions described their treatment as successful (78). Underlying depression and anxiety should be treated, and antidepressant medication may need adjustment. Bupropion may be an alternative to SSRIs, and one small, double-blind study reported increased sexual pleasure, arousal, and orgasm in nondepressed women with distressing low desire treated with bupropion (79). Sildenafil citrate may benefit women who develop problems with


Gynecology_Novak

Gynecology_Novak. reported increased sexual pleasure, arousal, and orgasm in nondepressed women with distressing low desire treated with bupropion (79). Sildenafil citrate may benefit women who develop problems with arousal and orgasmic response on SSRIs but generally is no more effective than placebo for most female sexual problems (80,81).


Gynecology_Novak

Gynecology_Novak. Despite the fact that sexual problems are common, the majority of women with distressing sexual problems do not seek formal care, but when they do, it is typically the woman, rather than the physician, who initiates the conversation (82,83). Clinicians should routinely ask their menopausal patients whether vaginal dryness, dyspareunia, or another bothersome sexual problem is present, as many effective interventions are available. There are many options available to address the health and quality of life concerns of menopausal women. The primary indication for hormone therapy is the alleviation of hot ﬂashes and associated symptoms. Women must be informed of the potential risks and benefits of all therapeutic options. Care should be individualized based on a woman’s medical history, needs, and preferences. 1. Adena M, Gallagher H. Cigarette smoking and the age at menopause. Ann Hum Biol 1982;9:121–130. 2.


Gynecology_Novak

Gynecology_Novak. 1. Adena M, Gallagher H. Cigarette smoking and the age at menopause. Ann Hum Biol 1982;9:121–130. 2. Siddle N, Sarrel P, Whitehead M. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 1987;47:94–100. 3. de Vet A, Laven J, de Jong F, et al. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357– 362. 4. Soules M, Sherman S, Parrott E, et al. Executive summary: stages of reproductive aging workshop (STRAW). Fertil Steril 2001;76:874– 878. 5. Schiff I, Regestein Q, Tulchinsky D, et al. Effects of estrogens on sleep and psychological state of the hypogonadal woman. JAMA 1979;242:2405–2407. 6. Freedman R, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot ﬂash-related thermoregulatory parameters. Menopause 2005;12:156–159. 7.


Gynecology_Novak

Gynecology_Novak. 6. Freedman R, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot ﬂash-related thermoregulatory parameters. Menopause 2005;12:156–159. 7. Kronenberg F, Barnard RM. Modulation of menopausal hot ﬂashes by ambient temperature. J Therm Biol 1992;17:43–49. 8. Gold E, Sternfeld B, Kelsey J, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epidemiol 2000;152:463– 473. 9. Whiteman M, Staropoli C, Langenberg P, et al. Smoking, body mass, and hot ﬂashes in midlife women. Obstet Gynecol 2003;101:264–272. 10. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805–813. 11. Krebs E, Ensrud K, MacDonald R, et al. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824–836. 12.


Gynecology_Novak

Gynecology_Novak. 11. Krebs E, Ensrud K, MacDonald R, et al. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824–836. 12. Newton K, Reed S, LaCroix A, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo. Ann Intern Med 2006;145:869–879. 13. Barton D, Loprinzi C, Quella S, et al. Prospective evaluation of vitamin E for hot ﬂashes in breast cancer survivors. J Clin Oncol 1998;16:495–500. 14. Avis N, Legault C, Coeytaux R, et al. A randomized, controlled pilot study of acupuncture treatment for menopausal hot ﬂashes. Menopause 2008;15:1070–1078. 15. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065– 1078. 16.


Gynecology_Novak

Gynecology_Novak. 16. Notelovitz M, Lenihan J, McDermott M, et al. Initial 17B-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726– 731. 17. Bachmann G, Schaefers M, Uddin A, et al. Lowest effective trans-dermal 17b-estradiol dose for relief of hot ﬂushes in postmenopausal women. Obstet Gynecol 2007;110:771–779. 18. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11:11–33. 19. Schiff I, Tulchinsky D, Cramer D, et al. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443– 1445. 20. Goodwin J, Green S, Moinpour C, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 2008;26:1650–1656. 21.


Gynecology_Novak

Gynecology_Novak. 21. Stearns V, Beebe K, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot ﬂashes. JAMA 2003:2827–2834. 22. Loprinzi C, Kugler J, Sloan J, et al. Venlafaxine in management of hot ﬂashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–2063. 23. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and ﬂuoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18–26. 24. Guttuso T, Kurlan R, McDermott M, et al. Gabapentin’s effects on hot ﬂashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337–345. 25. Soares C, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause. Obstet Gynecol 2006;108:1402–1410. 26.


Gynecology_Novak

Gynecology_Novak. 25. Soares C, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause. Obstet Gynecol 2006;108:1402–1410. 26. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause 2007;14:357–369. 27. Handa VL, Bachus KE, Johnston WW, et al. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84:215–218. 28. Henriksson L, Stjernquist M, Boquist L, et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiolreleasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996;174:85– 92. 29.


Gynecology_Novak

Gynecology_Novak. 29. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83–92. 30. Eriksen BC. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999;180:1072–1079. 31. Hendrix S, Cochrane B, Nygaard I, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293:935– 948. 32. National Osteoporosis Foundation. Fast facts on osteoporosis. www.nof.org.2010. 33. National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008. 34. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637– 1642. 35.


Gynecology_Novak

Gynecology_Novak. 34. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637– 1642. 35. Bischoff-Ferrari H, Willett W, Wong J, et al. Prevention of non-vertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:551–561. 36. Jackson R, LaCroix A, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669– 683. 37. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. Welcome to FRAX. Available at http://www.sheffield.ac.uk/FRAX/. A ccessed September 15, 2011. 38. Watts N, Ettinger B, LeBoff M. Perspective: FRAX facts. J Bone Min Res 2009;24:975–979. 39. Cauley J, Zmuda J, Ensrud K, et al. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001;86:5700–5705. 40.


Gynecology_Novak

Gynecology_Novak. 39. Cauley J, Zmuda J, Ensrud K, et al. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001;86:5700–5705. 40. Cauley J, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 2003;290:1729. 41. Ettinger B, Ensrud K, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obset Gynecol 2004;104:443–451. 42. Cummings S, Black D, Thompson D, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077–2082. 43. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis. JAMA 1999;282:1344–1352. 44. Black D, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.


Gynecology_Novak

Gynecology_Novak. 44. Black D, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822. 45. MORE Investigators. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637–645. 46. Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441. 47. Cummings S, San Martin J, McClung M, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–765. 48. Stampfer M, Colditz G, Willet W, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health Study. N Engl J Med 1991;325:756–762. 49.


Gynecology_Novak

Gynecology_Novak. 48. Stampfer M, Colditz G, Willet W, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health Study. N Engl J Med 1991;325:756–762. 49. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199–208. 50. Barrett-Connor I. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115:455–456. 51. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333. 52. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701–1712. 53.


Gynecology_Novak

Gynecology_Novak. 52. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701–1712. 53. Rossouw J, Prentice R, Manson J, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–1477. 54. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestins. Circulation 2007;115:840–845. 55. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–137. 56. Parkin D, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33–64. 57. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997;350:1047–1059. 58.


Gynecology_Novak

Gynecology_Novak. 57. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997;350:1047–1059. 58. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485–491. 59. Holmberg L, Anderson H. HABITS, a randomised comparison: trial stopped. Lancet 2003;363:453–455. 60. Vogel V, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006;295:2727–2741. 61. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000;283:1007–1015. 62. Shumaker S, Legault C, Rapp S, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women. JAMA 2003;289:2651–2662. 63.


Gynecology_Novak

Gynecology_Novak. 62. Shumaker S, Legault C, Rapp S, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women. JAMA 2003;289:2651–2662. 63. Espeland MA, Rapp S, Shumaker S, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004;291:2959– 2968. 64. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010;17:242–255. 65. American College of Obstetricians and Gynecologists. Hormone therapy. Obstet Gynecol 2004;104(Suppl 4):S1–S129. 66. Shifren J, Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010;115:839–855. 67. Archer D, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080. 68.


Gynecology_Novak

Gynecology_Novak. 67. Archer D, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080. 68. Ettinger B, Selby J, Citron JT, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693– 700. 69. Varila E, Wahlstrom T, Raura I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969–973. 70. Shifren J, Desindes S, McIlwain M, et al. A randomized, open label, crossover study comparing the effects of transdermal vs. oral estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985–994. 71. Shifren J, Monz B, Russo P, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970–978. 72.


Gynecology_Novak

Gynecology_Novak. 71. Shifren J, Monz B, Russo P, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970–978. 72. Avis N, Brockwell S, Randolph J, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause 2009;16:442–452. 73. Gast M, Freedman M, Vieweg A, et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 2009;16:247–526. 74. Shifren J, Braunstein G, Simon J, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–688. 75. Shifren J, Davis S, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause 2006;13:770–779. 76.